Pieris Pharmaceuticals Inc (PIRS) Expected to Announce Earnings of -$0.16 Per Share

Analysts expect Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to report earnings per share (EPS) of ($0.16) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Pieris Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.20) and the highest is ($0.12). Pieris Pharmaceuticals posted earnings of $0.17 per share in the same quarter last year, which indicates a negative year over year growth rate of 194.1%. The firm is scheduled to announce its next quarterly earnings results on Friday, March 8th.

According to Zacks, analysts expect that Pieris Pharmaceuticals will report full year earnings of ($0.45) per share for the current fiscal year, with EPS estimates ranging from ($0.49) to ($0.41). For the next year, analysts expect that the business will post earnings of ($0.82) per share, with EPS estimates ranging from ($1.07) to ($0.62). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The business had revenue of $8.35 million for the quarter, compared to analyst estimates of $6.16 million. Pieris Pharmaceuticals had a negative return on equity of 18.07% and a negative net margin of 17.90%.

A number of equities analysts have weighed in on the company. BidaskClub upgraded Pieris Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, September 26th. HC Wainwright set a $12.00 target price on Pieris Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 4th. Cowen restated a “buy” rating on shares of Pieris Pharmaceuticals in a research note on Sunday, November 11th. Finally, ValuEngine lowered Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $10.00.

Shares of NASDAQ PIRS opened at $3.39 on Monday. The stock has a market capitalization of $183.57 million, a price-to-earnings ratio of -8.48 and a beta of 1.94. Pieris Pharmaceuticals has a twelve month low of $3.04 and a twelve month high of $9.75.

In other Pieris Pharmaceuticals news, Director Christopher P. Kiritsy bought 5,000 shares of the firm’s stock in a transaction on Friday, September 14th. The shares were acquired at an average cost of $5.11 per share, for a total transaction of $25,550.00. Following the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at $51,100. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. 5.07% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in PIRS. Public Employees Retirement System of Ohio bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $110,000. Marshall Wace LLP bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $118,000. Bowling Portfolio Management LLC bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $156,000. California Public Employees Retirement System bought a new position in shares of Pieris Pharmaceuticals during the 2nd quarter valued at about $179,000. Finally, Alpine Global Management LLC increased its position in shares of Pieris Pharmaceuticals by 125.0% during the 2nd quarter. Alpine Global Management LLC now owns 45,000 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 25,000 shares during the last quarter. Hedge funds and other institutional investors own 64.85% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Featured Article: Penny Stocks

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply